+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
SPECT & PET Radiopharmaceuticals Market - Global Forecast 2026-2032- Product Image
SPECT & PET Radiopharmaceuticals Market - Global Forecast 2026-2032- Product Image
Sale

SPECT & PET Radiopharmaceuticals Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6078753
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The SPECT & PET Radiopharmaceuticals Market is projected to reach USD 8.18 Billion in 2026. It is expected to continue growing at a CAGR of 10.28%, reaching USD 14.85 Billion by 2032.

SPECT and PET Radiopharmaceuticals: Executive Overview

SPECT and PET radiopharmaceuticals support diagnostic imaging, disease staging, treatment planning, and selected therapeutic pathways across oncology, cardiology, neurology, and other specialties. Their use depends on isotope availability, validated production and distribution systems, imaging infrastructure, clinical guidelines, reimbursement, and specialist expertise. The field is evolving as healthcare systems seek earlier diagnosis, more precise characterization of disease, and imaging approaches that can be integrated with personalized care.

Clinical Integration and Supply Resilience Are Reshaping the Landscape

The landscape is being transformed by the expansion of molecular imaging applications, wider adoption of hybrid imaging, and greater emphasis on coordinated radiopharmaceutical supply. Short half-lives make production scheduling, quality control, transportation, and site-level workflow especially important. Regulatory harmonization, isotope access, radiochemistry capacity, and investment in PET and SPECT infrastructure increasingly influence whether clinical demand can be converted into routine patient access. At the same time, evidence requirements are strengthening as providers assess diagnostic value, patient outcomes, operational efficiency, and total care pathways.

Artificial Intelligence Is Improving Interpretation, Workflow, and Precision

Artificial intelligence is being applied to image reconstruction, attenuation correction, lesion detection, segmentation, quantification, motion management, and clinical decision support. In SPECT and PET, these tools can help address limited counts, reduce artifacts, standardize measurements, and support more reproducible interpretation. AI may also improve scheduling, protocol selection, radiopharmaceutical utilization, and quality assurance. Adoption remains dependent on representative validation datasets, interoperability, explainability, cybersecurity, regulatory clearance, and clinician oversight; performance should be evaluated across scanners, tracers, patient populations, and care settings rather than assumed from a single deployment.

Regional Insights: Infrastructure and Isotope Access Shape Adoption

North America benefits from established nuclear medicine services, advanced imaging infrastructure, and active clinical research, while access and reimbursement remain uneven across systems. Europe combines strong academic and hospital capabilities with cross-border regulatory and supply considerations, and the European Union places particular emphasis on coordinated health policy and isotope security. Asia-Pacific includes highly advanced markets alongside rapidly expanding imaging capacity, with Japan, China, South Korea, India, and Australia reflecting different regulatory, demographic, and infrastructure conditions. Latin America is developing molecular imaging access through major urban and private-sector centers, but distribution, funding, and workforce constraints can limit geographic coverage. The Middle East is investing in specialized hospitals and diagnostic capacity, especially in the Gulf, while radiopharmaceutical logistics and skilled staffing remain important. Africa presents substantial unmet diagnostic need alongside concentrated infrastructure, limited isotope supply, and a strong requirement for regional training and referral networks.

Group Insights: Economic Blocs and Alliances Influence Capability Building

ASEAN countries are pursuing healthcare modernization at different speeds, making cross-border logistics, workforce development, and compatible regulatory processes important for radiopharmaceutical access. BRICS members combine large patient populations with varied production capabilities, healthcare financing models, and domestic isotope strategies. The European Union supports collaboration around research, regulation, health technology assessment, and supply resilience, although national implementation still differs. G7 economies generally possess mature research and imaging ecosystems, with attention focused on innovation, safety, affordability, and supply continuity. GCC countries are strengthening tertiary-care and precision-medicine capacity, creating opportunities for centralized radiopharmacy and referral models. NATO members span diverse health systems, but shared interest in resilience, emergency preparedness, secure supply chains, and advanced medical capability can support cooperation in nuclear medicine.

Country Insights: Diverse Policy, Infrastructure, and Clinical Priorities

Australia combines strong specialist centers with geographic access challenges that make logistics and centralized production important. Brazil has substantial clinical need and capable urban institutions, while regional inequality and supply continuity remain central issues. Canada’s dispersed population increases the importance of coordinated distribution, workforce planning, and equitable access. China is expanding advanced imaging and domestic healthcare capabilities within a large and varied system. France, Germany, Italy, and Spain have established nuclear medicine services, with national reimbursement, regulatory processes, isotope supply, and hospital organization shaping uptake. India is developing capacity rapidly, but affordability, regional access, and specialist availability remain significant considerations. Japan has mature clinical expertise and a distinctive regulatory and reimbursement environment, while South Korea continues to integrate advanced imaging with technology-enabled care. Mexico is strengthening specialized diagnostic services, though access is concentrated geographically. Russia maintains nuclear medicine capabilities amid changing trade, regulatory, and supply conditions. The United Kingdom combines strong academic expertise and clinical networks with ongoing attention to workforce, commissioning, and resilient supply. The United States has extensive imaging infrastructure and research activity, while reimbursement, site economics, isotope availability, and equitable access influence utilization.

Priorities for Leaders: Build Resilient, Evidence-Led Radiopharmaceutical Pathways

Industry leaders should align investments with validated clinical use cases rather than technology novelty alone. Priorities include diversifying isotope and precursor supply, strengthening radiopharmacy quality systems, and designing logistics for short-lived products. Organizations should develop partnerships among hospitals, manufacturers, regulators, research institutions, and transport providers; standardize dosimetry and imaging protocols; and invest in specialist training. AI programs should begin with transparent governance, prospective validation, interoperability, and monitoring for bias and model drift. Leaders should also evaluate access across urban and rural settings, integrate health-economic evidence into adoption decisions, and use measurable indicators such as turnaround time, failed deliveries, protocol consistency, report quality, patient pathway completion, and clinical impact.

Methodology: Structured Synthesis of Clinical, Operational, and Policy Evidence

This executive summary uses a qualitative synthesis framework for SPECT and PET radiopharmaceuticals. The assessment considers clinical applications, isotope and radiopharmacy infrastructure, imaging workflow, regulation, reimbursement, workforce, supply resilience, digital technologies, and regional access. Comparisons across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific are interpreted alongside group-level perspectives covering ASEAN, BRICS, the European Union, G7, GCC, and NATO, and country-level considerations for the specified markets. Findings are framed as evidence-based strategic themes; they do not provide market estimates, market shares, forecasts, or company-specific assessments.

Conclusion: Access, Evidence, and Resilience Will Define Progress

SPECT and PET radiopharmaceuticals are becoming more closely connected to precision diagnosis, treatment planning, and integrated care. Progress will depend not only on tracer innovation, but also on dependable isotope supply, robust radiopharmacy operations, appropriate imaging capacity, skilled professionals, credible clinical evidence, and responsible digital adoption. Regions and countries that coordinate these elements can improve consistency and access, while fragmented systems may continue to experience delays and uneven utilization. A practical strategy therefore combines clinical validation, operational resilience, equitable deployment, and disciplined governance of AI and molecular imaging data.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. SPECT & PET Radiopharmaceuticals Market, by Modality
7.1. Introduction
7.2. PET
7.3. SPECT
8. SPECT & PET Radiopharmaceuticals Market, by Radiopharmaceutical Type
8.1. Introduction
8.2. Fluorine 18
8.2.1. FDG
8.2.2. Non FDG
8.3. Gallium 68
8.4. Indium 111
8.5. Iodine 123
8.6. Technetium 99M
8.6.1. Cold Kits
8.6.2. Ready To Use
9. SPECT & PET Radiopharmaceuticals Market, by Indication
9.1. Introduction
9.2. Cardiology
9.3. Neurology
9.4. Oncology
10. SPECT & PET Radiopharmaceuticals Market, by End User
10.1. Introduction
10.2. Academic And Research Institutes
10.3. Diagnostic Centers
10.4. Hospitals
11. SPECT & PET Radiopharmaceuticals Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. SPECT & PET Radiopharmaceuticals Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. SPECT & PET Radiopharmaceuticals Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. SPECT & PET Radiopharmaceuticals Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Advanced Accelerator Applications
16.2. Bayer AG
16.3. Bracco Imaging S.p.A.
16.4. Cardinal Health, Inc.
16.5. Curium Pharma
16.6. Eckert & Ziegler
16.7. GE Healthcare
16.8. IBA Molecular
16.9. Isotopia Molecular Imaging Ltd.
16.10. Jubilant Pharma Limited
16.11. Lantheus Holdings, Inc.
16.12. Life Molecular Imaging GmbH
16.13. Mallinckrodt plc
16.14. Nihon Medi-Physics Co., Ltd.
16.15. NorthStar Medical Radioisotopes, LLC
16.16. Novartis AG
16.17. Positron Corporation
16.18. Spectrum Pharmaceuticals, Inc.
16.19. Telix Pharmaceuticals Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global SPECT & PET Radiopharmaceuticals Market, Years Considered for the Study
FIGURE 2. Global SPECT & PET Radiopharmaceuticals Market, Research Design
FIGURE 3. Global SPECT & PET Radiopharmaceuticals Market, Research Framework
FIGURE 4. Global SPECT & PET Radiopharmaceuticals Market, Data Triangulation
FIGURE 5. Global SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
FIGURE 6. Global SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2025 vs 2032 (%)
FIGURE 7. Global SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2025 vs 2032 (%)
FIGURE 9. Global SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global SPECT & PET Radiopharmaceuticals Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global SPECT & PET Radiopharmaceuticals Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global SPECT & PET Radiopharmaceuticals Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global SPECT & PET Radiopharmaceuticals Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global SPECT & PET Radiopharmaceuticals Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global SPECT & PET Radiopharmaceuticals Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global SPECT & PET Radiopharmaceuticals Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global SPECT & PET Radiopharmaceuticals Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global SPECT & PET Radiopharmaceuticals Market Segmentation & Coverage
TABLE 2. Global SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 3. Global SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 4. Global PET Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global PET Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global PET Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global SPECT Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global SPECT Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global SPECT Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 11. Global Fluorine 18 Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Fluorine 18 Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Fluorine 18 Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global FDG Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global FDG Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global FDG Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Non FDG Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Non FDG Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Non FDG Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Gallium 68 Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Gallium 68 Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Gallium 68 Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Indium 111 Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Indium 111 Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Indium 111 Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Iodine 123 Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Iodine 123 Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Iodine 123 Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Technetium 99M Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Technetium 99M Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Technetium 99M Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Cold Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Cold Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Cold Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Ready To Use Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Ready To Use Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Ready To Use Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 39. Global Cardiology Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Cardiology Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Cardiology Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 49. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 59. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global SPECT & PET Radiopharmaceuticals Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific SPECT & PET Radiopharmaceuticals Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. North America SPECT & PET Radiopharmaceuticals Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. North America SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 76. North America SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 77. North America SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 78. North America SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 79. North America SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 80. North America SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. North America SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Latin America SPECT & PET Radiopharmaceuticals Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Latin America SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 84. Latin America SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 85. Latin America SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 86. Latin America SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 87. Latin America SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 88. Latin America SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Latin America SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. Europe SPECT & PET Radiopharmaceuticals Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Europe SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 92. Europe SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 93. Europe SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 94. Europe SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 95. Europe SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. Europe SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 97. Europe SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Middle East SPECT & PET Radiopharmaceuticals Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Middle East SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 100. Middle East SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 101. Middle East SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 102. Middle East SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 103. Middle East SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. Middle East SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Middle East SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Africa SPECT & PET Radiopharmaceuticals Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Africa SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 108. Africa SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 109. Africa SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 110. Africa SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 111. Africa SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. Africa SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. Africa SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. Global SPECT & PET Radiopharmaceuticals Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. ASEAN SPECT & PET Radiopharmaceuticals Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. ASEAN SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 117. ASEAN SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 118. ASEAN SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 119. ASEAN SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 120. ASEAN SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 121. ASEAN SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. ASEAN SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. GCC SPECT & PET Radiopharmaceuticals Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. GCC SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 125. GCC SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 126. GCC SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 127. GCC SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 128. GCC SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 129. GCC SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. GCC SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. European Union SPECT & PET Radiopharmaceuticals Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. European Union SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 133. European Union SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 134. European Union SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 135. European Union SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 136. European Union SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. European Union SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. European Union SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. BRICS SPECT & PET Radiopharmaceuticals Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. BRICS SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 141. BRICS SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 142. BRICS SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 143. BRICS SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 144. BRICS SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 145. BRICS SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. BRICS SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. G7 SPECT & PET Radiopharmaceuticals Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. G7 SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 149. G7 SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 150. G7 SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 151. G7 SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 152. G7 SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 153. G7 SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. G7 SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. NATO SPECT & PET Radiopharmaceuticals Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. NATO SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 157. NATO SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 158. NATO SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 159. NATO SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 160. NATO SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. NATO SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. NATO SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. Global SPECT & PET Radiopharmaceuticals Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. United States SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 165. United States SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 166. United States SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 167. United States SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 168. United States SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 169. United States SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. United States SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. United States SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. Canada SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 173. Canada SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 174. Canada SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 175. Canada SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 176. Canada SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 177. Canada SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. Canada SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. Canada SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. Mexico SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 181. Mexico SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 182. Mexico SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 183. Mexico SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 184. Mexico SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 185. Mexico SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 186. Mexico SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Mexico SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Brazil SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 189. Brazil SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 190. Brazil SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 191. Brazil SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 192. Brazil SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 193. Brazil SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 194. Brazil SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Brazil SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. United Kingdom SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 197. United Kingdom SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 198. United Kingdom SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 199. United Kingdom SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 200. United Kingdom SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 201. United Kingdom SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 202. United Kingdom SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. United Kingdom SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Germany SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 205. Germany SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 206. Germany SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 207. Germany SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 208. Germany SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 209. Germany SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 210. Germany SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. Germany SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. France SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 213. France SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 214. France SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 215. France SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 216. France SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 217. France SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 218. France SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. France SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. Russia SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 221. Russia SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 222. Russia SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 223. Russia SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 224. Russia SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 225. Russia SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. Russia SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. Russia SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. Italy SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 229. Italy SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 230. Italy SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 231. Italy SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 232. Italy SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 233. Italy SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. Italy SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Italy SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Spain SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 237. Spain SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 238. Spain SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 239. Spain SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 240. Spain SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 241. Spain SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 242. Spain SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. Spain SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. China SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 245. China SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 246. China SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 247. China SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 248. China SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 249. China SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. China SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. China SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. India SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 253. India SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 254. India SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 255. India SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 256. India SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 257. India SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 258. India SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. India SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. Japan SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 261. Japan SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 262. Japan SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 263. Japan SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 264. Japan SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 265. Japan SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 266. Japan SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. Japan SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. Australia SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 269. Australia SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 270. Australia SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 271. Australia SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 272. Australia SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 273. Australia SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 274. Australia SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Australia SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 276. South Korea SPECT & PET Radiopharmaceuticals Market Size, 2017-2032 (USD Million)
TABLE 277. South Korea SPECT & PET Radiopharmaceuticals Market Size, by Modality, 2017-2032 (USD Million)
TABLE 278. South Korea SPECT & PET Radiopharmaceuticals Market Size, by Radiopharmaceutical Type, 2017-2032 (USD Million)
TABLE 279. South Korea SPECT & PET Radiopharmaceuticals Market Size, by Fluorine 18, 2017-2032 (USD Million)
TABLE 280. South Korea SPECT & PET Radiopharmaceuticals Market Size, by Technetium 99M, 2017-2032 (USD Million)
TABLE 281. South Korea SPECT & PET Radiopharmaceuticals Market Size, by Indication, 2017-2032 (USD Million)
TABLE 282. South Korea SPECT & PET Radiopharmaceuticals Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. South Korea SPECT & PET Radiopharmaceuticals Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. Global SPECT & PET Radiopharmaceuticals Market Share, by Key Player, 2025
TABLE 285. Global SPECT & PET Radiopharmaceuticals Market, Key Experts

Companies Mentioned

  • Advanced Accelerator Applications
  • Bayer AG
  • Bracco Imaging S.p.A.
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler
  • GE Healthcare
  • IBA Molecular
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Life Molecular Imaging GmbH
  • Mallinckrodt plc
  • Nihon Medi-Physics Co., Ltd.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • Positron Corporation
  • Spectrum Pharmaceuticals, Inc.
  • Telix Pharmaceuticals Limited

Related Topics

Related Reports

Radiopharmaceuticals in Nuclear Medicine Market - Global Forecast 2026-2032 - Product Image

Radiopharmaceuticals in Nuclear Medicine Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Nuclear Medicine & Radiopharmaceuticals Market - Global Forecast 2026-2032 - Product Image

Nuclear Medicine & Radiopharmaceuticals Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Single Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography (PET) Radiopharmaceutical Market Report 2026 - Product Image

Single Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography (PET) Radiopharmaceutical Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Radiopharmaceutical Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

Radiopharmaceutical Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 84 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.